Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Total Current Liabilities
All obligations due within one year.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Total Current Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total current liabilities falls 94.9% from a year ago
Total current liabilities stood at $87.84K at the end of Q4 FY2025, down 94.9% from a year earlier. Over 3 fiscal years it compounded at -60.4% a year.
Context
- Total current liabilities amounted to 0.3% of total assets at the end of Q4 FY2025, down 8.9 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -94.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 87.84K USD
- Year-over-year change
- -94.9%
- 4-year CAGR
- -56.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 87.84K | -94.9% |
| FY2024 | 2024-12-31 | 1.73M | +74.2% |
| FY2023 | 2023-12-31 | 993.06K | -29.6% |
| FY2022 | 2022-12-31 | 1.41M | -40.7% |
| FY2021 | 2021-12-31 | 2.38M | — |
Total Current Liabilities vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -94.9% is the lowest of 10, against a peer median of +17.2%.
- Total current liabilities amounts to 0.3% of total assets for NNNN, versus a peer median of 17.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.57B USD | +8.3% | +0.3% | 19.5% | |
| Mar 2026 | $153.8M USD | +412.7% | +151.4% | 28.9% | |
| Mar 2026 | $131.2M USD | -4.4% | -4.7% | 12.5% | |
| Mar 2026 | $89.49M USD | +34.3% | +15.0% | 17.7% | |
| Mar 2026 | CA$86.73M CAD | -4.9% | +1.1% | 6.6% | |
| Feb 2026 | $66.07M USD | -15.3% | +0.8% | 25.3% | |
| Dec 2025 | $57.36M USD | — | — | 17.1% | |
| Mar 2026 | $56.51M USD | +17.2% | +8.8% | 43.8% | |
| Mar 2026 | $22.81M USD | +19.3% | -14.0% | 16.7% | |
| Mar 2026 | $9.48M USD | +38.1% | +16.6% | 10.1% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $87.84K USD | -94.9% | -60.4% | 0.3% |
| Peer median (excluding NNNN) | — | +17.2% | +1.1% | 17.4% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.